Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hospital program aims to keep COPD patients out of trouble after Flare-Ups

NCT ID NCT06646419

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests whether a structured care program (called a transition bundle) helps people with COPD recover better after a serious flare-up. The program includes guided steps and regular check-ins. About 1,368 patients across 36 hospitals will take part. The goal is to see if this approach reduces the chance of their condition getting worse again.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Post-exacerbation transition bundle (a set of care steps and audits)
What this could lead to
If successful, this program could become a standard way to help COPD patients avoid serious worsening after a flare-up.
What could go wrong
This is a cluster trial testing a care process, not a new drug. Results may vary by hospital and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,368 people

The number who actually took part.

Started

Nov 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The target population in this study are in the hospital exacerbation COPD patients with high risk of future exacerbation. Exacerbation COPD is defined as an event characterized by dyspnea and/or cough and sputum that worsen over \<14 days. Exacerbation of COPD are often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insults to the lungs.. Screening occurs when AECOPD identified in emergency room, respiratory outpatient clinic or inpatient department. Enrolment occurs when AECOPD treated for several days entering recovery period and transferring to home.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed COPD (post- bronchodilator FEV1/FVC \< 0.7) * 40\~80 years * CAT≥10 * At least two moderate or at least one severe exacerbation history in past 1 year * Able to sign informed consent Exclusion Criteria: * Continuous triple inhalation therapy for ≥6 months at baseline (include single inhaler and multiple inhalers) * Stable COPD (symptom such as cough, sputum and shortness of breath are mild or stable, clinical condition has basically returned to pre-exacerbation) * Comorbidities require/contraindicate long-term use of glucocorticoid treatment: asthma, interstitial lung disease, sarcoidosis, cystic fibrosis, active tuberculosis recurrent aspiration pneumonia ect. * Serious comorbidities threaten to life expected survival time no more than 1 year: severe heart disease, severe chronic liver, severe kidney disease, cerebrovascular disease with long-term bed rest and malignant tumours ect. * Not living in the healthcare area * Patients currently participating in any other interventional studies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

  • Research Site

    Anyang, China

  • Research Site

    Baise City, China

  • Research Site

    Beijing, China

  • Research Site

    Bijie, China

  • Research Site

    Changsha, China

  • Research Site

    Chenzhou, China

  • Research Site

    Chifeng, China

  • Research Site

    Chuzhou, China

  • Research Site

    Deyang, China

  • Research Site

    Fuyang, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Jieyang, China

  • Research Site

    Jining, China

  • Research Site

    Jiujiang, China

  • Research Site

    Kaiyuan, China

  • Research Site

    Langfang, China

  • Research Site

    Langzhong, China

  • Research Site

    Leping, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanchong, China

  • Research Site

    Neijiang, China

  • Research Site

    Qiannan, China

  • Research Site

    Qujing, China

  • Research Site

    Sanmenxia, China

  • Research Site

    Shaoyang, China

  • Research Site

    Suzhou, China

  • Research Site

    Tengzhou, China

  • Research Site

    Tieling, China

  • Research Site

    Wenzhou, China

  • Research Site

    Xiangtan, China

  • Research Site

    Xiaogan, China

  • Research Site

    Xinyang, China

  • Research Site

    Yancheng, China

  • Research Site

    Yichang, China

  • Research Site

    Yuling, China

  • Research Site

    Zaoyang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.